Delving into the Latest Updates on SP-100075 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SP-100207 (Signal)

Target

NFKB1

Mechanism

NFKB1 modulators(Nuclear factor kappa B modulators)

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Inflammation

Originator Organization

Signal Research Corp.

Active Organization-

Inactive Organization

Signal Research Corp.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Daily treatment of rats bearing Yoshida AH-130 ascites hepatoma with the nuclear factor kappa-B (NF-kappaB) and activator protein-1 (AP-1) double inhibitors SP100030 and SP100207 at a dose of 5 mg/kg and 10 mg/kg of body weight, respectively, resulted in a clear inhibition of tumour growth. The decrease was not related to an altered cell cycle distribution of the tumour cell population suggesting a merely necrotic effect. The results presented confirm that both transcription factors are involved in the growth of the experimental tumour system used, suggesting that both signaling cascades play a very important role in the signaling of tumour cell proliferation. This could, in future, allow for the development of new therapeutic strategies for cancer patients.

100 Deals associated with SP-100075

Login to view more data